期刊
AMERICAN JOURNAL OF EPIDEMIOLOGY
卷 181, 期 6, 页码 363-368出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/aje/kwv011
关键词
big data; clinical trials; cohort studies; epidemiology; public health; training
资金
- Zoll Lifecor
- Johnson Johnson
- Boehringer Ingelheim
- Bristol Myers Squibb
- Pfizer
- Gilead Sciences
- GlaxoSmithKline
- Eli Lilly
- Medicine's Company
- Astra Zeneca
- Daiichi Sankyo
- Janssen Pharmaceuticals
- Salix Pharmaceuticals
- Bayer
- Hoffmann-La Roche
- Armetheon
- Medtronic Foundation
- Merck Co.
- Sanofi-Aventis
- Takeda
In 2013, the National Heart, Lung, and Blood Institute assembled a working group on epidemiology and population sciences from its Advisory Council and Board of External Experts. The working group was charged with making recommendations to the National Heart, Lung, and Blood Advisory Council about how the National Heart, Lung, and Blood Institute could take advantage of new scientific opportunities and delineate future directions for the epidemiology of heart, lung, blood, and sleep diseases. Seven actionable recommendations were proposed for consideration. The themes included 1) defining the compelling scientific questions and challenges in population sciences and epidemiology of heart, lung, blood, and sleep diseases; 2) developing methods and training mechanisms to integrate big data science into the practice of epidemiology; 3) creating a cohort consortium and inventory of major studies to optimize the efficient use of data and specimens; and 4) fostering a more open, competitive approach to evaluating large-scale longitudinal epidemiology and population studies. By building on the track record of success of the heart, lung, blood, and sleep cohorts to leverage new data science opportunities and encourage broad research and training partnerships, these recommendations lay a strong foundation for the transformation of heart, lung, blood, and sleep epidemiology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据